Appili Therapeutics Inc has held steady this week, reflecting a cautious market sentiment.
Appili Therapeutics Inc (APLI.TO) has recently experienced stagnant price action, with no significant changes in its stock performance over the past week. As the company continues to navigate its financial landscape, investors are keeping a close eye on developments in the health care sector that could impact its future.
Investor takeaway: With a market cap of approximately C$1.99 million and a significant negative return on equity, investors should approach Appili Therapeutics with caution, particularly given its recent performance and market conditions.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.21
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
146.1%
Annualized
90-Day Vol
206.5%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.02 |
| 60 trading days | C$0.02 | C$0.01 – C$0.03 |
| 90 trading days | C$0.02 | C$0.01 – C$0.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Appili Therapeutics Sees Stagnant Performance with Significant Challenges Ahead
With a year-to-date decline of 40% and a current share price of C$0.01, Appili's stock reflects considerable market skepticism.
Bull case
There’s still potential for growth, especially since analysts suggest an implied upside. The company’s ongoing initiatives, including the commercial momentum of LIKMEZ® and funding from NIAID, could drive future performance.
Bear case
On the flip side, the company faces challenges like a declining stock price and a substantial negative return on equity, which may deter risk-averse investors.
Current Price Action
Appili Therapeutics Inc's stock closed at C$0.01, reflecting no change over the past week. This stagnant performance aligns with broader trends in the health care sector, where investor sentiment remains cautious.
Company News and Developments
Recently, there hasn’t been any major news directly impacting Appili Therapeutics' stock. However, the company did report its fiscal year 2026 financial results earlier this year, highlighting commercial momentum for its product LIKMEZ® and a US$40 million NIAID award that supports the advancement of VXV-01. This funding may provide some cushion for the company as it seeks to improve its operational outlook.
Technical Picture
From a technical standpoint, Appili's stock is currently trading below both its 50-day moving average (C$0.02) and 200-day moving average (C$0.02), indicating a bearish trend. The stock has a 52-week trading range of C$0.01 to C$0.04, with only 17% of this range being utilized. The current beta of -0.21 suggests that the stock is less volatile than the market, which may appeal to conservative investors. Recent trading volume has been low, with only 7,000 shares traded against a 20-day average of 52,058 shares, indicating reduced investor interest.
Insider Activity
There have been no recent insider transactions reported for Appili Therapeutics, which may indicate a lack of confidence from current executives or a strategic pause in trading activities.
Price Action Summary
As of the last close, Appili Therapeutics Inc remains at C$0.01, unchanged from the previous day. With a year-to-date decline of 40%, investors are left to weigh the potential for recovery against the backdrop of ongoing financial challenges.
Advertisement
